Last reviewed · How we verify
BOTOX ® 200 Unités
BOTOX (botulinum toxin type A) blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis.
BOTOX (botulinum toxin type A) blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Hemifacial spasm.
At a glance
| Generic name | BOTOX ® 200 Unités |
|---|---|
| Sponsor | University Hospital, Clermont-Ferrand |
| Drug class | Neurotoxin; botulinum toxin type A |
| Target | SNARE complex (specifically cleaves SNAP-25) |
| Modality | Small molecule |
| Therapeutic area | Neurology; Aesthetics; Pain Management |
| Phase | Phase 3 |
Mechanism of action
Botulinum toxin type A cleaves SNARE proteins required for acetylcholine vesicle fusion and release at the presynaptic terminal. This results in flaccid paralysis of the injected muscle that typically lasts 3-4 months. The effect is reversible as the body gradually regenerates the cleaved proteins and forms new neuromuscular junctions.
Approved indications
- Cervical dystonia
- Blepharospasm
- Hemifacial spasm
- Chronic migraine
- Overactive bladder
- Spasticity
- Cosmetic wrinkle reduction
Common side effects
- Headache
- Neck pain
- Muscle weakness
- Injection site pain
- Flu-like symptoms
- Eyelid ptosis
- Diplopia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |